Exploratory radiomic features from integrated
Aged
Aged, 80 and over
Algorithms
Cluster Analysis
Esophageal Neoplasms
/ diagnostic imaging
Female
Fluorodeoxyglucose F18
Gastrointestinal Neoplasms
/ diagnostic imaging
Humans
Image Processing, Computer-Assisted
Magnetic Resonance Imaging
Male
Middle Aged
Multimodal Imaging
Multivariate Analysis
Neoplasm Metastasis
Patient Satisfaction
Positron-Emission Tomography
Predictive Value of Tests
Prospective Studies
Radiopharmaceuticals
/ therapeutic use
Reproducibility of Results
Risk Assessment
Sensitivity and Specificity
18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging
Oesophageal cancer
Radiomic analysis
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
29
08
2018
accepted:
04
03
2019
pubmed:
29
3
2019
medline:
15
7
2020
entrez:
29
3
2019
Statut:
ppublish
Résumé
The purpose of this study was to determine if Following IRB approval and informed consent, patients underwent a staging PET/MRI following Twenty patients (18 males, 2 female; median 67 years, range 52-86) comprised the final study cohort; ten patients had metastases. Lower second-order SUV entropy combined with higher second-order ADC entropy were the best feature-pair for discriminating metastatic patients, MANOVA p value <0.001 (SN = 80%, SP = 80%, PPV = 80%, NPV = 80%, ACC = 80%). SUV High ADC entropy combined with low SUV entropy is associated with a higher prevalence of metastases and a promising initial signature for future study.
Identifiants
pubmed: 30919055
doi: 10.1007/s00259-019-04306-7
pii: 10.1007/s00259-019-04306-7
pmc: PMC6533412
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1478-1484Subventions
Organisme : Cancer Research UK
ID : C1519/A16463
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT203148/Z/16/Z
Pays : United Kingdom
Références
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Cancer. 2007 Aug 1;110(3):686-93
pubmed: 17582628
J Nucl Med. 2008 Mar;49(3):480-508
pubmed: 18287273
J Nucl Med. 2009 Apr;50(4):520-6
pubmed: 19289430
J Clin Oncol. 2009 Oct 20;27(30):5062-7
pubmed: 19770374
J Nucl Med. 2011 Mar;52(3):369-78
pubmed: 21321270
Semin Radiat Oncol. 2011 Apr;21(2):119-40
pubmed: 21356480
Br J Radiol. 2012 Sep;85(1017):e694-701
pubmed: 22337686
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1345-55
pubmed: 23715903
Radiology. 2013 Aug;268(2):318-22
pubmed: 23882093
Mol Clin Oncol. 2014 Mar;2(2):313-321
pubmed: 24649354
J Nucl Med. 2014 Aug;55(8):1242-7
pubmed: 24868109
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2008-16
pubmed: 25037871
Radiother Oncol. 2015 May;115(2):163-70
pubmed: 26002307
J Magn Reson Imaging. 2016 Jan;43(1):213-9
pubmed: 26013043
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
J Nucl Med. 2016 May;57(5):691-700
pubmed: 26795288
Eur J Radiol. 2016 Mar;85(3):540-5
pubmed: 26860665
Oncotarget. 2016 Oct 11;7(41):66623-66634
pubmed: 27579613
Nat Genet. 2016 Oct;48(10):1131-41
pubmed: 27595477
Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):206-214
pubmed: 27613542
J Nucl Med. 2017 May;58(5):723-729
pubmed: 27738011
Dis Esophagus. 2017 Feb 1;30(3):1-8
pubmed: 27862622
Eur J Surg Oncol. 2017 Feb;43(2):471-477
pubmed: 27912930
EJNMMI Res. 2017 Dec;7(1):35
pubmed: 28429332
Eur Radiol. 2018 Jan;28(1):428-436
pubmed: 28770406
Nucl Med Commun. 2018 Jan;39(1):60-67
pubmed: 29023336
Eur Radiol. 2018 Oct;28(10):4296-4305
pubmed: 29725833
Acta Oncol. 2018 Sep;57(9):1201-1208
pubmed: 29781342